CADTH rapid response report: Olopatadine for the treatment of allergic conjunctivitis

Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Rapid Response Report from the Canadian Agency for Drugs and Technologies in Health (CADTH) evaluated the efficacy, safety and cost-effectiveness of olopatadine, in comparison with ketotifen, cromolyn, or placebo to assist in the decision making with respect to these agents for the treatment of allergic conjunctivitis.   A limited literature search found that "Treatment of allergic conjunctivitis with olopatadine, ketotifen or cromolyn showed reductions in signs and symptom scores compared to baseline. Both olopatadine and ketotifen were (Read more...)

Full Story →